title: Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma.
abstract: OBJECTIVE
  Angiogenesis is a characteristic of renal cell carcinoma. ABT-510 is an angiogenesis inhibitor that mimics the antiangiogenic properties of thrombospondin-1. This study was designed to assess the safety and efficacy of ABT-510 in patients with advanced renal cell carcinoma.
  
  
  METHODS
  Patients with previously untreated metastatic or unresectable renal cell carcinoma were randomized to treatment with one of two doses of ABT-510, self-administered s.c. twice daily in 28-day treatment periods without intervening rest periods. End points were progression-free survival (PFS), objective response rate, overall survival, and toxicity.
  
  
  RESULTS
  The objective response rate was 4% in the 10 mg twice daily group, and there were two unconfirmed PRs in the 100 mg twice daily group. Respective median PFS was 4.2 and 3.3 months, with a 6-month PFS of 39% and 32%. Median overall survival was 27.8 months (10 mg twice daily) and 26.1 months (100 mg twice daily). The most frequent adverse events were injection site reactions (84%), fatigue (50%), headache (20%), and nausea (19%). The incidence of treatment-related, grade 3/4 adverse events was low and included three bleeding episodes (gastrointestinal hemorrhage, intracranial hemorrhage, and hemoptysis) and one thrombotic event (deep vein thrombosis). No deaths were attributed to ABT-510.
  
  
  CONCLUSIONS
  There was little evidence of clinical activity for ABT-510, and further evaluation as a single agent for treating advanced renal cell carcinoma is not warranted. The evidence of a favorable safety profile may justify further evaluation in combination therapy.
authors.affiliation: Arizona Cancer Center, Tucson, AZ, USA. Scot_Ebbinghaus@merck.com
authors.forename: Scot
authors.initials: S
authors.lastname: Ebbinghaus
authors.forename: Maha
authors.initials: M
authors.lastname: Hussain
authors.forename: Nizar
authors.initials: N
authors.lastname: Tannir
authors.forename: Michael
authors.initials: M
authors.lastname: Gordon
authors.forename: Apurva A
authors.initials: AA
authors.lastname: Desai
authors.forename: Raymond A
authors.initials: RA
authors.lastname: Knight
authors.forename: Rod A
authors.initials: RA
authors.lastname: Humerickhouse
authors.forename: Jiang
authors.initials: J
authors.lastname: Qian
authors.forename: Gary B
authors.initials: GB
authors.lastname: Gordon
authors.forename: Robert
authors.initials: R
authors.lastname: Figlin
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; C500617:NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt; D009842:Oligopeptides